Michelino De Laurentiis

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Medicine, Oncology, Pharmacology +14

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Debu Tripathy, Seock‐Ah Im, Marco Colleoni et al. · The Lancet Oncology · 2018 · 1K citations

Medicine, Oncology, Pharmacology +16

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · New England Journal of Medicine · 2019 · 841 citations · Full text

Medicine, Oncology, Pharmacology +14

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Sylvia Adams, Sherene Loi, Deborah Toppmeyer et al. · Annals of Oncology · 2018 · 631 citations

Medicine, Oncology, Pharmacotherapy +17